▶ 調査レポート

グルカゴン様ペプチド-1(GLP-1)アゴニストの世界市場 2020年

• 英文タイトル:Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。グルカゴン様ペプチド-1(GLP-1)アゴニストの世界市場 2020年 / Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 / GIR201111428資料のイメージです。• レポートコード:GIR201111428
• 出版社/出版日:GlobalInfoResearch / 2020年10月20日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、101ページ
• 納品方法:Eメール
• 産業分類:医薬品・医療
• 販売価格(消費税別)
  Single User¥515,040 (USD3,480)▷ お問い合わせ
  Multi User¥772,560 (USD5,220)▷ お問い合わせ
  Corporate User¥1,030,080 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本書では、グルカゴン様ペプチド-1(GLP-1)アゴニストの世界市場を調査対象にし、グルカゴン様ペプチド-1(GLP-1)アゴニストの市場概要、メーカー情報、メーカー別販売量・売上・市場シェア、地域別市場分析(北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ)、種類別分析(エクセナチド、リラグルチド、リキシセナチド、アルビグルチド、デュラグルチド)、用途別分析(病院、薬局、その他)、市場予測(2021年~2025年)、販売チャンネル・代理店分析情報などを整理しました。
・市場概要
・メーカー情報:Novo Nordisk、GSK、AstraZeneca、Amylin、Eli Lilly、Bristol-Myers Squibb、Sanofi
・メーカー別販売量、売上、市場シェア
・グルカゴン様ペプチド-1(GLP-1)アゴニストの地域別市場分析
・グルカゴン様ペプチド-1(GLP-1)アゴニストの北米市場規模2015-2020:アメリカ、カナダ、メキシコ
・グルカゴン様ペプチド-1(GLP-1)アゴニストのヨーロッパ市場規模2015-2020:ドイツ、イギリス、フランス、ロシアなど
・グルカゴン様ペプチド-1(GLP-1)アゴニストのアジア市場規模2015-2020:日本、中国、韓国、インド、東南アジアなど
・グルカゴン様ペプチド-1(GLP-1)アゴニストの南米市場規模2015-2020:ブラジル、アルゼンチンなど
・グルカゴン様ペプチド-1(GLP-1)アゴニストの中東・アフリカ市場規模2015-2020:サウジアラビア、トルコ、エジプト、南アフリカなど
・グルカゴン様ペプチド-1(GLP-1)アゴニストの種類別市場規模2015-2020:エクセナチド、リラグルチド、リキシセナチド、アルビグルチド、デュラグルチド
・グルカゴン様ペプチド-1(GLP-1)アゴニストの用途別市場規模2015-2020:病院、薬局、その他
・グルカゴン様ペプチド-1(GLP-1)アゴニストの世界市場予測2021-2025:地域別、種類別、用途別
・販売チャンネル・代理店分析
・調査の結果・結論

Market Overview
The Glucagon Like Peptide-1 (GLP-1) Agonists market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Glucagon Like Peptide-1 (GLP-1) Agonists market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 12.7%% in the forecast period of 2020 to 2025 and will expected to reach USD 11310 million by 2025, from USD 7001.5 million in 2019.

Market segmentation
Glucagon Like Peptide-1 (GLP-1) Agonists market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Glucagon Like Peptide-1 (GLP-1) Agonists market has been segmented into
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide

By Application, Glucagon Like Peptide-1 (GLP-1) Agonists has been segmented into:
Hospital
Pharmacy
Other

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Glucagon Like Peptide-1 (GLP-1) Agonists market presented in the report. This section sheds light on the sales growth of different regional and country-level Glucagon Like Peptide-1 (GLP-1) Agonists markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Glucagon Like Peptide-1 (GLP-1) Agonists market.

The report offers in-depth assessment of the growth and other aspects of the Glucagon Like Peptide-1 (GLP-1) Agonists market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)

Competitive Landscape and Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Analysis
Glucagon Like Peptide-1 (GLP-1) Agonists competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Glucagon Like Peptide-1 (GLP-1) Agonists sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Glucagon Like Peptide-1 (GLP-1) Agonists sales, revenue and market share for each player covered in this report.

The major players covered in Glucagon Like Peptide-1 (GLP-1) Agonists are:
Novo Nordisk
GSK
AstraZeneca
Amylin
Eli Lilly
Bristol-Myers Squibb
Sanofi

Among other players domestic and global, Glucagon Like Peptide-1 (GLP-1) Agonists market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glucagon Like Peptide-1 (GLP-1) Agonists product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, with price, sales, revenue and global market share of Glucagon Like Peptide-1 (GLP-1) Agonists in 2018 and 2019.
Chapter 3, the Glucagon Like Peptide-1 (GLP-1) Agonists competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glucagon Like Peptide-1 (GLP-1) Agonists breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Glucagon Like Peptide-1 (GLP-1) Agonists market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Glucagon Like Peptide-1 (GLP-1) Agonists sales channel, distributors, customers, research findings and conclusion, appendix and data source.

レポート目次

1 Market Overview
1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Exenatied
1.2.3 Liraglutide
1.2.4 Lixisenatide
1.2.5 Albiglutide
1.2.6 Dulaglutide
1.3 Market Analysis by Application
1.3.1 Overview: Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Overview of Global Glucagon Like Peptide-1 (GLP-1) Agonists Market
1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Novo Nordisk
2.1.1 Novo Nordisk Details
2.1.2 Novo Nordisk Major Business
2.1.3 Novo Nordisk SWOT Analysis
2.1.4 Novo Nordisk Product and Services
2.1.5 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK SWOT Analysis
2.2.4 GSK Product and Services
2.2.5 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca SWOT Analysis
2.3.4 AstraZeneca Product and Services
2.3.5 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Amylin
2.4.1 Amylin Details
2.4.2 Amylin Major Business
2.4.3 Amylin SWOT Analysis
2.4.4 Amylin Product and Services
2.4.5 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 Eli Lilly
2.5.1 Eli Lilly Details
2.5.2 Eli Lilly Major Business
2.5.3 Eli Lilly SWOT Analysis
2.5.4 Eli Lilly Product and Services
2.5.5 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Bristol-Myers Squibb
2.6.1 Bristol-Myers Squibb Details
2.6.2 Bristol-Myers Squibb Major Business
2.6.3 Bristol-Myers Squibb Product and Services
2.6.4 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.7 Sanofi
2.7.1 Sanofi Details
2.7.2 Sanofi Major Business
2.7.3 Sanofi Product and Services
2.7.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturer Market Share in 2019
3.3.2 Top 6 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Regions
4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Regions (2015-2020)
4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Regions (2015-2020)
4.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
4.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
4.5 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Country
5.1.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Country (2015-2020)
5.1.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Country (2015-2020)
5.2 United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
5.3 Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
5.4 Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Country
6.1.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Country (2015-2020)
6.1.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Country (2015-2020)
6.2 Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
6.3 UK Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
6.4 France Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
6.5 Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
6.6 Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Regions (2015-2020)
7.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
7.3 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
7.4 Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
7.5 India Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
7.7 Australia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Country
8.1.1 South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Country (2015-2020)
8.1.2 South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Country (2015-2020)
8.2 Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
8.3 Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
9.3 Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
9.4 Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
9.5 South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share by Type (2015-2020)
10.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Market Share by Type (2015-2020)
10.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2015-2020)
11 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Segment by Application
11.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2015-2020)
11.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (2015-2020)
11.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2015-2020)
12 Market Forecast
12.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Growth Rate (2021-2025)
12.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast by Regions (2021-2025)
12.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2021-2025)
12.2.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2021-2025)
12.2.3 Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2021-2025)
12.2.4 South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2021-2025)
12.2.5 Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2021-2025)
12.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast by Type (2021-2025)
12.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2021-2025)
12.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Type (2021-2025)
12.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast by Application (2021-2025)
12.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2021-2025)
12.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US

List of Tables
Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Growth Estimation in Various Scenarios in 2020
Table 4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 5. Market Opportunities in Next Few Years
Table 6. Market Risks Analysis
Table 7. Market Drivers
Table 8. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 9. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Major Business
Table 10. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Total Revenue (USD Million) (2018-2019)
Table 11. Novo Nordisk SWOT Analysis
Table 12. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
Table 13. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 14. GSK Basic Information, Manufacturing Base and Competitors
Table 15. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Major Business
Table 16. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Total Revenue (USD Million) (2018-2019)
Table 17. GSK SWOT Analysis
Table 18. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
Table 19. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 20. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 21. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Major Business
Table 22. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Total Revenue (USD Million) (2018-2019)
Table 23. AstraZeneca SWOT Analysis
Table 24. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
Table 25. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 26. Amylin Basic Information, Manufacturing Base and Competitors
Table 27. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Major Business
Table 28. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Total Revenue (USD Million) (2018-2019)
Table 29. Amylin SWOT Analysis
Table 30. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
Table 31. Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 32. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 33. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Major Business
Table 34. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Total Revenue (USD Million) (2018-2019)
Table 35. Eli Lilly SWOT Analysis
Table 36. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
Table 37. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 38. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 39. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Major Business
Table 40. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Total Revenue (USD Million) (2018-2019)
Table 41. Bristol-Myers Squibb SWOT Analysis
Table 42. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
Table 43. Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 44. Sanofi Basic Information, Manufacturing Base and Competitors
Table 45. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Major Business
Table 46. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Total Revenue (USD Million) (2018-2019)
Table 47. Sanofi SWOT Analysis
Table 48. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product and Services
Table 49. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 50. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Manufacturer (2018-2019) (K Units)
Table 51. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Manufacturer (2018-2019) (USD Million)
Table 52. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Regions (2015-2020) (K Units)
Table 53. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Regions (2015-2020)
Table 54. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Regions (2015-2020) (USD Million)
Table 55. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Countries (2015-2020) (K Units)
Table 56. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Countries (2015-2020)
Table 57. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Countries (2015-2020) (USD Million)
Table 58. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Countries (2015-2020)
Table 59. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Countries (2015-2020) (K Units)
Table 60. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Countries (2015-2020)
Table 61. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Countries (2015-2020) (USD Million)
Table 62. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Regions (2015-2020) (K Units)
Table 63. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Regions (2015-2020)
Table 64. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Regions (2015-2020) (USD Million)
Table 65. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Countries (2015-2020) (K Units)
Table 66. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Countries (2015-2020)
Table 67. South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Countries (2015-2020) (USD Million)
Table 68. South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Countries (2015-2020)
Table 69. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Countries (2015-2020) (K Units)
Table 70. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Countries (2015-2020)
Table 71. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Countries (2015-2020) (USD Million)
Table 72. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Countries (2015-2020)
Table 73. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2015-2020) (K Units)
Table 74. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2015-2020)
Table 75. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2015-2020) (USD Million)
Table 76. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2015-2020)
Table 77. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2015-2020) (K Units)
Table 78. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2015-2020)
Table 79. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Regions (2021-2025) (K Units)
Table 80. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Regions (2021-2025)
Table 81. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2021-2025) (K Units)
Table 82. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Type (2021-2025)
Table 83. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2021-2025)
Table 84. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share Forecast by Application (2021-2025)
Table 85. Direct Channel Pros & Cons
Table 86. Indirect Channel Pros & Cons
Table 87. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Picture
Figure 2. Global Sales Market Share of Glucagon Like Peptide-1 (GLP-1) Agonists by Type in 2019
Figure 3. Exenatied Picture
Figure 4. Liraglutide Picture
Figure 5. Lixisenatide Picture
Figure 6. Albiglutide Picture
Figure 7. Dulaglutide Picture
Figure 8. Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2019
Figure 9. Hospital Picture
Figure 10. Pharmacy Picture
Figure 11. Other Picture
Figure 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Status and Outlook (2015-2025) (USD Million)
Figure 13. United States Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 14. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 15. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 17. France Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 18. UK Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 21. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Korea Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 24. India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Australia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 27. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 30. South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (Value) and Growth Rate (2015-2025)
Figure 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Manufacturer in 2019
Figure 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Manufacturer in 2019
Figure 34. Top 3 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturer (Revenue) Market Share in 2019
Figure 35. Top 6 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturer (Revenue) Market Share in 2019
Figure 36. Key Manufacturer Market Share Trend
Figure 37. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 38. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Growth Rate (2015-2020) (USD Million)
Figure 39. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Regions (2015-2020)
Figure 40. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Regions in 2018
Figure 41. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
Figure 42. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
Figure 44. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
Figure 45. Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020)
Figure 46. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Growth Rate (2015-2020) (USD Million)
Figure 47. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Countries (2015-2020)
Figure 48. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Countries in 2018
Figure 49. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 50. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Countries in 2018
Figure 51. United States Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 52. Canada Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 53. Mexico Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 54. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Growth Rate (2015-2020) (USD Million)
Figure 55. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Countries (2015-2020)
Figure 56. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Countries in 2019
Figure 57. Germany Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 58. UK Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 59. France Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 60. Russia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 61. Italy Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 62. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Growth Rate (2015-2020) (USD Million)
Figure 63. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Regions 2019
Figure 64. Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Regions 2019
Figure 65. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 66. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 67. Korea Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 68. India Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 69. Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 70. South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Growth Rate (2015-2020) (USD Million)
Figure 71. South America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Countries in 2019
Figure 72. South America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Countries in 2019
Figure 73. Brazil Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 74. Argentina Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 75. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Growth Rate (2015-2020) (USD Million)
Figure 76. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Countries in 2019
Figure 77. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Countries (2015-2020)
Figure 78. Middle East and Africa Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Countries in 2019
Figure 79. Saudi Arabia Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 80. Egypt Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 81. Turkey Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 82. South Africa Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2015-2020) (K Units)
Figure 83. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Growth Rate (2021-2025) (K Units)
Figure 84. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue and Growth Rate (2021-2025) (USD Million)
Figure 85. North America Sales Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2021-2025) (K Units)
Figure 86. Europe Sales Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2021-2025) (K Units)
Figure 87. Asia-Pacific Sales Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2021-2025) (K Units)
Figure 88. South America Sales Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2021-2025) (K Units)
Figure 89. Middle East & Africa Sales Glucagon Like Peptide-1 (GLP-1) Agonists Market Forecast (2021-2025) (K Units)
Figure 90. Sales Channel: Direct Channel vs Indirect Channel